Boston Scientific announced that it has obtained an exclusive $200 million option to acquire Israel's MValve Technologies, maker of a transcatheter mitral valve replacement system for mitral regurgitation. Boston Scientific also said it is providing additional financing to the company in anticipation of a first in-human clinical trial.
Europe's Novocure has won an expanded indication for a 2011 FDA approval of its Optune to treat newly diagnosed glioblastoma in combination with temozolomide, a standard chemotherapy. The company has been on a roll of late, disclosing a CE mark for its second-generation version of Optune on Oct. 5 and pricing a $165 million IPO on Oct. 2.
Researchers nabbed a $6.8 million, 5-year grant from the National Institutes of Health to develop technology to predict, track and treat epileptic seizures. The grant is part of the ongoing BRAIN (Brain Research Through Advancing Innovative Neurotechnologies) Initiative launched by President Obama.
The federal Centers for Medicare and Medicaid Services (CMS) employs a staff of 30 people to evaluate some 30,000 molecular tests, according to panelists speaking at discussion on improving the value proposition of diagnostics during the AdvaMed med tech conference.
POPULAR COMMENT THREADS
Memphis, TN's Tru-D SmartUVC touted the results of a study funded by the U.S. Centers for Disease Control and Prevention, which found that its ultraviolet light-emitting robot reduced the risk of acquiring hospital-associated infection by more than 30%.
The FDA has signed off on Israeli devicemaker InSightec's ultrasound technology to treat women with uterine fibroids who want to conceive, a win for the company as it pushes for new indications of its product and reels in funding to spur R&D.
The Wyss Institute for Biologically Inspired Engineering at Harvard University has launched startup Opsonix to develop its pathogen-extracting, extracorporeal sepsis device. Hansjörg Wyss, who founded the Institute with a $125 million gift in 2008, also participated in an $8 million Series A round that was led by Baxter Ventures.
Remote patient monitoring isn't a core business for Boston Scientific, but it is looking to gain access to the most cutting-edge tech in the field. It's launched the Boston Scientific Connected Patient Challenge: an open innovation challenge to solicit ideas and collaborations for remote patient monitoring.
The feds rejected a whistleblower's complaints that the FDA erred when it approved imaging devices for breast and colon cancer screening.
The FDA just approved its first third-generation bioabsorbable stent, to the delight of Boston Scientific.
From Our Sister Sites
Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.
Biogen, Sanofi and Novartis are all touting new data showing long-term benefits for their respective meds at this year's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS meeting)--and with tough new competition on the way, they may need it.